Substance-Induced Psychoses: An Updated Literature Review
A. Fiorentini, Filippo Cantù, Camilla Crisanti, Guido Cereda, Lucio Oldani, Paolo Brambilla
Frontiers in Psychiatry December 23, 2021 DOI: 10.3389/fpsyt.2021.694863 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Narrative review Peer reviewed |
|---|---|
| Population | General (substance-induced psychosis) |
| Topics | Addiction Cannabis |
| Keywords | Psychosis Psychotomimetic Hallucinogen Substance abuse Psychogenic disease Clinical psychology |
| Citations | 123 |
| Key findings | Psychosis due to substance abuse is commonly observed in clinical practice, and the propensity to develop psychosis appears to be a function of the severity of use and addiction. |
Abstract
Background: On the current psychopharmacological panorama, the variety of substances able to provoke an episode of acute psychosis is rapidly increasing. Such psychotic episodes are classified according to the major category of symptoms: positive, negative, or cognitive psychotic episodes. On one hand, the abuse of methamphetamines, cannabis, and cocaine plays a big role in increasing the incidence of episodes resembling a psychotic disorder. On the other hand, the progress in terms of pharmacodynamics knowledge has led to the synthesis of new drugs, such as cannabinoids and cathinone's, which have rapidly entered into the common pool of abusers' habits. Regarding these newly synthesized substances of abuse, further clinical studies are needed to understand their psychogenic properties. The topic of this review is complicated due to the frequent abuse of psychotomimetic drugs by patients affected by psychotic disorders, a fact that makes it extremely difficult to distinguish between an induced psychosis and a re-exacerbation of a previously diagnosed disorder.
Methods: The present narrative review summarizes results from clinical studies, thus investigating the psychotogenic properties of abused substances and the psychotic symptoms they can give rise to. It also discusses the association between substance abuse and psychosis, especially with regards to the differential diagnosis between a primary vs. a substance-induced psychotic disorder.
Findings: Our findings support the theory that psychosis due to substance abuse is commonly observed in clinical practice. The propensity to develop psychosis seems to be a function of the severity of use and addiction. Of note, from a phenomenological point of view, it is possible to identify some elements that may help clinicians involved in differential diagnoses between primary and substance-induced psychoses. There remains a striking paucity of information on the outcomes, treatments, and best practices of substance-induced psychotic episodes.
In the evidence
This study is part of the evidence base for a synthesis in the library. Here is how each one recorded it.
-
Reports that abuse of methamphetamine, cannabis and cocaine plays a large role in increasing episodes resembling psychotic disorder, with psychosis propensity a function of severity of use and addiction.
Synthesized
Comparable studies
Other narrative reviews on cannabis for addiction, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| The neuropsychopharmacology of cannabis: A review of human imaging studies | 2018 | Review | |
| New psychoactive substances of natural origin: A brief review | 2017 | Review | |
| New Psychoactive Substances (NPS) – a Challenge for the Addiction Treatment Services | 2017 | Review | |
| Classic Psychedelics in Addiction Treatment: The Case for Psilocybin in Tobacco Smoking Cessation | 2022 | Review | |
| Policy in focus: Is psilocybin the next cannabis? | 2021 | Review |
Citations in the library
Cited by 18
- Characterizing Thalamocortical (Dys)connectivity Following D-Amphetamine, LSD, and MDMA Administration Biological Psychiatry: Cognitive Neuroscience and Neuroimaging April 29, 2022
- Longitudinal associations between psychedelic use and psychotic symptoms in the United States and the United Kingdom Journal of Affective Disorders January 26, 2024
- Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies. Molecular Psychiatry March 1, 2025
- Ecstasy, molly, MDMA: What health practitioners need to know about this common recreational drug. Disease-a-month : DM March 1, 2025
- Novel psychoactive substances (NPS) as a risk factor for psychosis: A systematic review of the literature Neuroscience & Biobehavioral Reviews October 19, 2025
and 13 more in the library
Cites 32
- Altered States of Consciousness Archives of General Psychiatry September 1, 1966
- Differences Between the Mechanism of Action of MDMA, MBDB, and the Classic Hallucinogens. Identification of a New Therapeutic Class: Entactogens Journal of Psychoactive Drugs October 1, 1986
- Psychiatry & the psychedelic drugs. Past, present & future. Neuropharmacology December 25, 2017
- Psychedelics and Mental Health: A Population Study PLoS One August 19, 2013
- Novel psychoactive substances of interest for psychiatry World Psychiatry February 1, 2016
and 27 more in the library